TRIPASS XR تري باس

In a systematic review of five randomized controlled trials

comparing COCs containing drospirenone to placebo or other COCs for effect on

premenstrual symptoms, the authors concluded that drospirenone 3 mg plus ethinyl

estradiol 20 mcg may help treat PMDD better than placebo.

177 They were unable to

determine whether this combination would help women with less severe symptoms

or would be more effective than other COCs. For women desiring contraception,

these particular agents have only been evaluated for efficacy in PMDD when used for

up to three cycles. The effects of other contraceptive agents for PMDD symptoms are

currently under investigation.

p. 1025

p. 1026

Table 50-6

Menstrual Cycle Daily Diary Chart

Month 1

Grading Severity of Symptoms:

1 = Mild; general awareness of discomfort but does not interfere with daily activities

2 = Moderate; interferes with activities but not disabling

3 = Severe; symptoms disabling, unable to meet daily social, family, or work obligations

* = Menstrual bleeding

Blank = no symptoms

Each Day

1. List the myour menstr2. Grade th3. Record d4. Record b5. Check thDay of month 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Day of menstrual

cycle

18 19 20 21 22 23 24 25 26 27 28 1 2 3 4 5

Menses * * * *

Breast tenderness

and pain

1 1 1 1 1 1 1 1

Sadness or

depression

1 2 3 3 3 3 3 3 2 1

Fatigue 3 3 3 3 3 3 3 3 2 1

Irritability 2 2 3 3 3 3 3

Inability to

concentrate

2 2 3 3 3

Daily weight (lb) 130 130 130 130 130 130 130 130 130 130 130 131 131 131 130 130

Basal body

temperature (°F)

98.0 98.2 98.0 98.2 98.0 98.0 98.2 97.8 98.0 97.8 97.6 97.8

Month 2

Day of month 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16

Day of menstrual

cycle

21 22 23 24 25 26 27 28 1 2 3 4 5 6 7 8

Menses * * * *

Breast tenderness

and pain

1 1 1 1 1 1 1

Sadness/depression 1 2 3 3 3 3 3 2 2 1

Fatigue 2 2 3 3 3 3 3 2 1

Irritability 1 2 2 2 3 3 3 3 3 2 2 1

Inability to

concentrate

1 1 2 2 3 3

Daily weight (lb) 128 128 128 128 128 128 128 129 129 129 128 128 128 128 128 128

Basal body

temperature (°F)

98.0 98.2 98.4 98.0 98.2 97.8 98.0 97.4 97.6 97.6 97.8 97.8

p. 1026

p. 1027

Table 50-7

Psychotropic Drugs for the Management of Premenstrual Syndrome or

Premenstrual Dysphoric Disorder

Drug (Brand Name)

Daily Dosing Regimen

(mg) Intermittent Dosing Regimen (mg)

a

SSRI

Citalopram (Celexa) 5–30 10–30

Escitalopram (Lexapro) 10–20 10–20

Fluoxetine (Prozac or Sarafem

b

) 20–60 20 or 90 weekly

Fluvoxamine (Luvox) 50–150 NS

Paroxetine (Paxil) 10–30 NS

Paroxetine controlled release (Paxil CR)

b 12.5–25 12.5–25

Sertraline (Zoloft)

b 50–150 100

Other Serotonergic Antidepressants

Nefazodone (Serzone) 200–600 NS

Venlafaxine (Effexor) 50 NS

Anxiolytics

Alprazolam (Xanax) NS 1–2

c

Buspirone (BuSpar) NS 25–60

aDay 14 until onset of menses.

bMedication has FDA-approved indication for premenstrual dysphoric disorder.

cDose to be tapered during 2 days after onset of menses to prevent withdrawalsymptoms.

NS, not studied; SSRI, selective serotonin reuptake inhibitors.

OTHER AGENTS

Treatment with GnRH agonists has been used for the physical and psychological

symptoms of PMS.

178 These agents are not typically used for long periods of time,

however, because of vasomotor symptoms and the potential for negative long-term

effects on bone. They also have to be administered by injection or nasal spray which

may affect adherence. This treatment is reserved for women with very severe PMDD

who do not respond to other treatments.

Danazol has been investigated for the treatment of PMS with moderate results.

Danazol 200 mg orally BID provides greater symptom relief than placebo for

symptoms of severe PMS; however, luteal phase treatment does not appear effective

for PMS symptoms.

179 Potential side effects are also a concern with this agent, and

therefore, its use in women should be limited to those who have failed other

therapies.

C.P. has PMDD and does not need contraception because she uses condoms. Mood

symptoms predominate and are impairing her functionality. An SSRI should be

started in either a continuous or intermittent manner. C.P. appears to be a good

candidate for intermittent therapy because she can adhere to the regimen and does not

have a concurrent depression or anxiety disorder. An appropriate initial treatment

regimen is fluoxetine 20 mg orally daily for the last 2 weeks of the menstrual cycle.

Her response rate should be assessed after three cycles of treatment. An anxiolytic

could be tried for symptoms not relieved by the SSRI.

KEY REFERENCES AND WEBSITES

A full list of references for this chapter can be found at

http://thepoint.lww.com/AT11e. Below are the key references and websites for this

chapter, with the corresponding reference number in this chapter found in parentheses

after the reference.

Key References

American College of Obstetricians and Gynecologists. ACOG Practice Bulletin No. 114. Management of

endometriosis. Obstet Gynecol. 2010;116:223. (116)

Brown J, Farquhar C. Endometriosis: an overview of Cochrane Reviews. Cochrane Database Syst Rev. 2014;

(3):CD009590. doi:10.1002/14651858.CD009590.pub2.

Legro RS, et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice

guideline. J Clin Endocrinol Metab. 2013;98:4565–4592.

Nevatte T et al. ISPMD consensus on the management of premenstrual disorders. Arch Womens Ment Health.

2013;16:279–291.

O’Brien PMS, Backstrom T, Brown C, et al. Towards a consensus on diagnostic criteria, measurement and trial

design of the premenstrual disorders: the ISPMD Montreal consensus. Arch Womens Ment Health. 2011;14:13–

21

Zahradnik HP et al. Nonsteroidal anti-inflammatory drugs and hormonal contraceptives for pain relief from

dysmenorrhea: a review. Contraception. 2010;81:185. (99)

Key Websites

Androgen Excess and PCOS Society. http://www.ae-society.org. Accessed June 16, 2017.

Polycystic Ovarian Support Association. http://www.pcosupport.org. Accessed June 16, 2017.

COMPLETE REFERENCES CHAPTER 50 DISORDERS

RELATED TO THE MENSTRUAL CYCLE

Hatcher RA et al. Contraceptive Technology. 20th ed. New York, NY: Ardent Media; 2011.

Hatcher RA et al. Contraceptive Technology. 17th rev. ed. New York, NY: Ardent Media; 1998.

Speroff L et al. Clinical Gynecologic Endocrinology and Infertility. 6th ed. Philadelphia, PA: Lippincott Williams &

Wilkins; 1999.

Fauser BCJ et al. Consensus on women’s health aspects of polycystic ovary syndrome (PCOS): the Amsterdam

ESHRE/ASRM-Sponsored 3rd PCOS Consensus Workshop Group. Fertil Steril. 2012;97:28–38.

Stein IF, Leventhal ML. Amenorrhea associated with bilateral polycystic ovaries. Am J Obstet Gynecol.

1935;29:181.

Stein IF. Bilateral polycystic ovaries. Am J Obstet Gynecol. 1945;50:385.

National Institutes of Health. Evidence-based methodology workshop on polycystic ovary syndrome: final report.

https://prevention.nih.gov/docs/programs/pcos/FinalReport.pdf. Accessed June 12, 2015.

ZawadskiJK, Dunaif A. Diagnostic criteria for polycystic ovary syndrome: towards a rational approach. In: Dunaif

A et al, eds. Polycystic Ovary Syndrome. Boston, MA: Blackwell Scientific Publications; 1992:377.

Rotterdam ESHRE/ASRM-Sponsored PCOS Consensus Workshop Group. Revised 2003 consensus on diagnostic

criteria and long-term health risks related to polycystic ovary syndrome. Fertil Steril. 2004;81:19.

Azziz R et al. The Androgen Excess and PCOS Society criteria for the polycystic ovary syndrome: the complete

task force report. Fertil Steril. 2009;91:456.

Azziz R et al. Position statement: criteria for defining polycystic ovary syndrome as a predominantly

hyperandrogenic syndrome: an Androgen Excess Society guideline. J Clin Endocrinol Metab. 2006;91:4237.

Legro RS et al. Diagnosis and treatment of polycystic ovary syndrome: an Endocrine Society clinical practice

guideline. J Clin Endocrinol Metab. 2013;98:4565–4592.

Azziz R et al. Androgen excess in women: experience with over 1,000 consecutive patients. J Clin Endocrinol

Metab. 2004;89:453.

Dahlgren E et al. Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long-term follow-up

focusing on natural history and circulating hormones. Fertil Steril. 1992;57:505–513.

Hoeger KM. Obesity and lifestyle management in polycystic ovary syndrome. Clin Obstet Gynecol. 2007;50:277.

Nam Menke M, Strauss JF 3rd. Genetics of polycystic ovary syndrome. Clin Obstet Gynecol. 2007;50:188.

Ehrmann DA. Polycystic ovary syndrome. N EnglJ Med. 2005;352:1223.

Ehrmann DA et al. Polycystic ovary syndrome as a form of functional ovarian hyperandrogenism due to

dysregulation of androgen secretion. Endocr Rev. 1995;16:322.

Nelson VL et al. The biochemical basis for increased testosterone production in theca cells propagated from

patients with polycystic ovary syndrome. J Clin Endocrinol Metab. 2001;86:5925.

Dunaif A. Insulin resistance in women with polycystic ovary syndrome. Fertil Steril. 2006;86(Suppl 1):S13.

Corbould A et al. Insulin resistance in the skeletal muscle of women with PCOS involves intrinsic and acquired

defects in insulin signaling. Am J Physiol Endocrinol Metab. 2005;288:E1047.

Dunaif A et al. Excessive insulin receptor serine phosphorylation in cultured fibroblasts and in skeletal muscle: a

potential mechanism for insulin resistance in the polycystic ovary syndrome. J Clin Invest. 1995;96:801.

Baillargeon JP et al. Insulin sensitizers for polycystic ovary syndrome. Clin Obstet Gynecol. 2003;46:325.

Meyer C et al. Effects of medical therapy on insulin resistance and the cardiovascular system in polycystic

ovary syndrome. Diabetes Care. 2007;30:471.

Tsilchorozidou T et al. The pathophysiology of the polycystic ovary syndrome. Clin Endocrinol. 2004;60:1.

Lorenz LB, Wild RA. Evaluation and management of diabetes and cardiovascular risks for today’s clinician. Clin

Obstet Gynecol. 2007;50:226.

Moran LJ et al. Impaired glucose tolerance, type 2 diabetes and metabolic syndrome in polycystic ovary

syndrome: a systematic review and meta-analysis. Hum Reprod Update. 2010;16:347–363.

Legro RS et al. Prevalence and predictors of risk for type 2 diabetes mellitus and impaired glucose tolerance in

polycystic ovary syndrome: a prospective, controlled study in 254 affected women. J Clin Endocrinol Metab.

1999;84:165.

Salley KE et al. Glucose intolerance in polycystic ovary syndrome—a position statement of the Androgen Excess

Society. J Clin Endocrinol Metab. 2007;92:4546.

American Association of Clinical Endocrinologists Polycystic Ovary Syndrome Writing Committee. American

Association of Clinical Endocrinologists position statement on metabolic and cardiovascular consequences of

polycystic ovary syndrome. Endocr Pract. 2005;11:126.

Glueck CJ et al. Incidence and treatment of metabolic syndrome in newly referred women with confirmed

polycystic ovarian syndrome. Metabolism. 2003;52:908.

Apridonidze T et al. Prevalence and characteristics of the metabolic syndrome in women with polycystic ovary

syndrome. J Clin Endocrinol Metab. 2005;90:1929.

Ehrmann DA et al. Prevalence and predictors of the metabolic syndrome in women with polycystic ovary

syndrome. J Clin Endocrinol Metab. 2006;91:48.

Expert Panel on Detection, Evaluation, and Treatment of High Blood Cholesterol in Adults. Executive summary

of the third report of the National Cholesterol Education Program (NCEP). JAMA. 2001;285:2486.

Essah PA et al. The metabolic syndrome in polycystic ovary syndrome. Clin Obstet Gynecol. 2007;50:205.

Grundy SM et al. Diagnosis and management of the metabolic syndrome. An American Heart

Association/National Heart, Lung, and Blood Institute scientific statement [published corrections appear in

Circulation. 2005;112:e297; Circulation. 2005;112:e298]. Circulation. 2005;112:2735.

Dahlgren E et al. Women with polycystic ovary syndrome wedge resected in 1956 to 1965: a long-term follow-up

focusing on natural history and circulating hormones. Fertil Steril. 1992;57:505.

Talbott E et al. Coronary heart disease risk factors in women with polycystic ovary syndrome. Arterioscler

Thromb Vasc Biol. 1995;15:821.

Pirwany IR et al. Lipids and lipoprotein subfractions in women with PCOS: relationship to metabolic and

endocrine parameters. Clin Endocrinol. 2001;54:447.

Wild RA et al. Assessment of cardiovascular risk and prevention of cardiovascular disease in women with the

polycystic ovary syndrome: a consensus statement by the Androgen Excess and Polycystic Ovary Syndrome

(AE-PCOS) Society. J Clin Endocrinol Metab. 2010;95:2038.

Fogel RB et al. Increased prevalence of obstructive sleep apnea syndrome in obese women with polycystic ovary

syndrome. J Clin Endocrinol Metab. 2001;86:1175.

Gopal M et al. The role of obesity in the increased prevalence of obstructive sleep apnea syndrome in patients

with polycystic ovary syndrome. Sleep Med. 2002;3:401.

Vgontzas AN et al. Polycystic ovary syndrome is associated with obstructive sleep apnea and daytime sleepiness:

role of insulin resistance. J Clin Endocrinol Metab. 2001;86:517.

Moran LJ et al. Lifestyle changes in women with polycystic ovary syndrome. Cochrane Database Syst Rev.

2011;(2):CD007506.

Huber-Buchholz MM et al. Restoration of reproductive potential by lifestyle modification in obese polycystic

ovary syndrome: role of insulin sensitivity and luteinizing hormone. J Clin Endocrinol Metab. 1999;84:1470.

Moran LJ et al. Dietary composition in restoring reproductive and metabolic physiology in overweight women with

polycystic ovary syndrome. J Clin Endocrinol Metab. 2003;88:812.

Schouten LJ et al. Anthropometry, physical activity, and endometrial cancer risk: results from the Netherlands

Cohort Study. J Natl Cancer Inst. 2004;96:1635.

Trentham-Dietz A et al. Weight change and risk of endometrial cancer. Int J Epidemiol. 2006;35:151.

Knowler WC et al. Reduction in the incidence of type 2 diabetes with lifestyle intervention or metformin. N EnglJ

Med. 2002;346:393.

Orchard TJ et al. The effect of metformin and intensive lifestyle modification on the metabolic syndrome: the

Diabetes Prevention Program randomized trial. Ann Intern Med. 2005;142:611.

Marsh K, Brand-Miller J. The optimal diet for women with polycystic ovary syndrome? Br J Nutr. 2005;94:154.

Kasim-Karakas SE et al. Relation of nutrients and hormones in polycystic ovary syndrome. Am J Clin Nutr.

2007;85:688.

American Heart Association. American Heart Association Guidelines.

http://www.heart.org/HEARTORG/GettingHealthy/PhysicalActivity/American-Heart-AssociationGuidelines-UCM-307976-Article.isp. Accessed March 1, 2011.

Cibula D et al. Insulin sensitivity in non-obese women with polycystic ovary syndrome during treatment with oral

contraceptives containing low androgenic progestin. Hum Reprod. 2002;17:76.

Diamanti-Kandarakis E et al. A modern medical quandary: polycystic ovary syndrome, insulin resistance, and oral

contraceptive pills. J Clin Endocrinol Metab. 2003;88:1927.

Costello M et al. Insulin-sensitising drugs versus the combined oral contraceptive pill for hirsutism, acne and risk

of diabetes, cardiovascular disease, and endometrial cancer in polycystic ovary syndrome. Cochrane Database

Syst Rev. 2007;(1):CD005552.

Pike MC et al. Estrogen-progestin replacement therapy and endometrial cancer. J Natl Cancer Inst.

1997;89:1110.

Vessey MP, Painter R. Endometrial and ovarian cancer and oral contraceptives—findings in a large cohort study.

Br J Cancer. 1995;71:1340.

Weiderpass E et al. Use of oral contraceptives and endometrial cancer risk (Sweden). Cancer Causes Control.

1999;10:277.

Baillargeon JP et al. Effects of metformin and rosiglitazone, alone and in combination, in nonobese women with

polycystic ovary syndrome and normal indices of insulin sensitivity. Fertil Steril. 2004;82:893.

Mansfield R et al. Metformin has direct effects on human ovarian steroidogenesis. Fertil Steril. 2003;79:956.

Thessaloniki ESHRE/ASRM sponsored PCOS consensus workshop group. Consensus on infertility treatment

related to polycystic ovary syndrome. Fertil Steril. 2008;89:505–22.

Tang T et al. Insulin-sensitising drugs (metformin, rosiglitazone, pioglitazone, D-chiro-inositol) for women with

polycystic ovary syndrome, oligoamenorrhoea and subfertility. Cochrane Database Syst Rev. 2010;

(1):CD003053.

Bautukan C, Muderris II. Efficacy of a new oral contraceptive containing drospirenone and ethinyl estradiol in the

long-term treatment of hirsutism. Fertil Steril. 2006;85:436.

Ganie MA et al. Comparison of efficacy of spironolactone with metformin in the management of polycystic ovary

syndrome: an open label study [published correction appears in J Clin Endocrinol Metab. 2004;89:4655]. J Clin

Endocrinol Metab. 2004;89:2756.

Moghetti P et al. Comparison of spironolactone, flutamide, and finasteride efficacy in the treatment of hirsutism: a

randomized, double blind, placebo-controlled trial. J Clin Endocrinol Metab. 2000;85:89.

Guzick DS. Ovulation induction management of PCOS. Clin Obstet Gynecol. 2007;50:255.

Al-Omari WR et al. Comparison of two aromatase inhibitors in women with clomiphene-resistant polycystic ovary

syndrome. Int J Gynaecol Obstet. 2004;85:289.

Elnashar A et al. Clomiphene citrate and dexamethasone in the treatment of clomiphene-resistant PCOS: a

prospective placebo-controlled study. Hum Reprod. 2006;21:1805.

Holzer H et al. A new era in ovulation induction. Fertil Steril. 2006;85:277.

Mitwally MF, Casper RF. Aromatase inhibition: a novel method of ovulation induction in women with polycystic

ovarian syndrome. Reprod Technol. 2000;10:244.

Casper RF, Mitwally MF. Review: aromatase inhibitors for ovulation induction. J Clin Endocrinol Metab.

2006;91:760–771.

Legro RS et al. Letrozole versus clomiphene for infertility in the polycystic ovary syndrome. N Engl J Med.

2014;371:119–129.

Palomba S et al. Ovulation induction in women with polycystic ovary syndrome. Fertil Steril. 2006;86(Suppl

1):S26.

Davis AR, Westhoff CL. Primary dysmenorrhea in adolescent girls and treatment with oral contraceptives. J

Pediatr Adolesc Gynecol. 2001;14:3.

Ju H et al. The prevalence and risk factors of dysmenorrhea. Epidemiol Rev. 2014;36:104–113.

Harel Z. Dysmenorrhea in adolescents and young adults: etiology and management. J Pediatr Adolesc Gynecol.

2006;19:363.

Dawood MY. Primary dysmenorrhea. Advances in pathogenesis and management. Obstet Gynecol.

2006;108:428.

100.

101.

102.

103.

104.

105.

106.

107.

108.

109.

110.

111.

112.

Latthe P et al. Factors predisposing women to chronic pelvic pain:systematic review. BMJ. 2006;332:749.

French L. Dysmenorrhea. Am Fam Physician. 2005;71:285.

Harlow SD, Ephross SA. Epidemiology of menstruation and its relevance to women’s health. Epidemiol Rev.

1995;17:265.

Society of Obstetricians and Gynaecologists of Canada. Primary dysmenorrhea consensus guidelines. J Obstet

Gynaecol Can. 2005;169:1119.

Brown J, Brown S. Exercise for dysmenorrhoea. Cochrane Database Syst Rev. 2010;(2):CD004142.

doi:10.1002/14651858.CD004142.pub2.

Rakhshaee Z. Effect of three yoga poses (cobra, cat and fish poses) in women with primary dysmenorrhea: a

randomized clinical trial. J Pediatr Adolsec Gynecol. 2011;24;192–196.

Akin M et al. Continuous low-level topical heat wrap therapy as compared to acetaminophen for primary

dysmenorrhea. J Reprod Med. 2004;49:739.

Akin MD et al. Continuous low level topical heat in the treatment of dysmenorrhea. Obstet Gynecol. 2001;97:343.

Navvabi Rigi S et al. Comparing the analgesic effect of heat patch containing iron chip and ibuprofen for primary

dysmenorrhea: a randomized controlled trial. BMC Womens Health. 2012;12:25.

Barnard ND et al. Diet and sex hormone binding globulin, dysmenorrhea, and premenstrual symptoms. Obstet

Gynecol. 2000;95:245.

Proctor ML, Murphy PA. Herbal and dietary therapies for primary and secondary dysmenorrhea. Cochrane

Database Syst Rev. 2001;(3):CD002124.

Zhang WY, Li Wan Po A. Efficacy of minor analgesics in primary dysmenorrhea: a systematic review. Br J

Obstet Gynaecol. 1998;105:780.

Lasco A et al. Improvement of primary dysmenorrhea caused by a single oral dose of vitamin D: results of a

randomized, double blind, placebo controlled study. Arch Intern Med. 2012;172;366–367.

Marjoribanks J et al. Nonsteroidal anti-inflammatory drugs for dysmenorrhoea. Cochrane Database Syst Rev.

2015;(7):CD001751. doi:10.1002/14651858.CD001751.pub3.

DuRant RH et al. Factors influencing adolescents’ responses to regimens of naproxen for dysmenorrhea. Am J

Dis Child. 1985;139:489.

Zahradnik HP et al. Nonsteroidal anti-inflammatory drugs and hormonal contraceptives for pain relief from

dysmenorrhea: a review. Contraception. 2010;81:185.

Wong CL et al. Oral contraceptive pill for primary dysmenorrhoea. Cochrane Database Syst Rev. 2009;

(4):CD002120.

Davis AR et al. Oral contraceptives for dysmenorrhea in adolescent girls: a randomized trial. Obstet Gynecol.

2005;106:97.

Dmitrovic R et al. Continuous compared with cyclic oral contraceptives for the treatment of primary

dysmenorrhea: a randomized controlled trial. Obstet Gynecol 2012;119;1143–1150.

Baldaszti E et al. Acceptability of the long term contraceptive levonorgestrel releasing intrauterine system: a 3-

year follow up study. Contraception. 2003;67:87.

Lobo R. Endometriosis: Etiology, Pathology, Diagnosis and Management. Philadelphia, PA: Mosby Elsevier; 2007.

Fuldeore M et al. Healthcare utilization and costs in women diagnosed with endometriosis before and after

diagnosis: a longitudinal analysis of claims databases. Fertil Steril. 2015; 103:163–171.

Kennedy S. Should a diagnosis of endometriosis be sought in allsymptomatic women? Fertil Steril. 2006;86:1312.

Boardman R, Jackson B. Below thebelt: approach to chronic pelvic pain. Can Fam Physician. 2006;52:1557.

Jackson B, Telner DE. Managing the misplaced: approach to endometriosis. Can Fam Physician. 2006;52:1422.

American Fertility Society for Reproductive Medicine. Revised American Fertility Society for Reproductive

Medicine classification of endometriosis: 1996. Fertil Steril. 1997;67:817.

Ferrero S et al. Antiangiogenic therapies in endometriosis. Br J Pharmacol. 2006;149:133.

Winkel CA. Evaluation and management of women with endometriosis. Obstet Gynecol. 2003;102:397.

Bulun SE. Mechanisms of disease: endometriosis. N EnglJ Med. 2009;360:268.

Farquhar C. Endometriosis. BMJ. 2007;334:249.

Missmer SA et al. Incidence of laparoscopically confirmed endometriosis by demographic, anthropometric, and

lifestyle factors. Am J Epidemiol. 2004;160:784.

Lin SY et al. Reproducibility of the revised American Fertility Society classification of endometriosis using

laparoscopy or laparotomy. Int J Gynaecol Obstet. 1998;60:265.

ACOG. Practice bulletin no. 114: management of endometriosis. Obstet Gynecol. 2010;116:223.

Barbieri RL. Endometriosis and the estrogen threshold theory: relation to surgical and medical treatment. J

113.

114.

115.

116.

117.

118.

119.

120.

121.

122.

123.

124.

125.

126.

127.

128.

129.

130.

131.

132.

133.

134.

135.

136.

137.

138.

139.

140.

Reprod Med. 1998;43:287.

Reddish S. Dysmenorrhea. Aust Fam Physician. 2006;35:82.

McLeod BS, Retzloff MG. Epidemiology of endometriosis: an assessment of risk factors. Clin Obstet Gynecol.

2010;53:389.

Fauconnier A et al. Relation between pain symptoms and the anatomic location of deep infiltrating

endometriosis. Fertil Steril. 2002;78:719.

Fauconnier A, Chapron C. Endometriosis and pelvic pain: epidemiological evidence of the relationship and

implications. Hum Reprod Update. 2005;11:595.

Kaatz J et al. Coping with endometriosis. J Obstet Gynecol Neonatal Nurs. 2010;39:220.

Cahill DJ. What is the optimal medical management of infertility and minor endometriosis? Analysis and future

prospects. Hum Reprod. 2002;17:1135.

Mahutte NG, Arici A. New advances in the understanding of endometriosis related infertility. J Reprod

Immunol. 2002;55:78.

Fassbender A et al. Biomarkers of endometriosis. Fertil Steril. 2013;99:1135–1145.

Dunselman GA et al. ESHRE guideline: management of women with endometriosis. Hum Reprod. 2014;29:400–

412.

Brown J, Farquhar C. Endometriosis: an overview of Cochrane Reviews. Cochrane Database Syst Rev. 2014;

(3):CD009590. doi:10.1002/14651858.CD009590.pub2.

Verellini P et al. Continuous use of an oral contraceptive for endometriosis associated recurrent dysmenorrhea

that does not respond to a cyclic pill regimen. Fertil Steril. 2003;80:560.

Seracchioli R et al. Long-term cyclic and continuous oral contraceptive therapy and endometrioma recurrence: a

randomized controlled trial. Fertil Steril. 2010;93:52.

Muzil L et al. Continuous versus cyclic oral contraceptives after laparoscopic excision of ovarian

endometriomas: a systematic review and metaanalysis. Am J Obstet Gynecol. 2016;214:203–211.

Petta C et al. Randomized clinical trial of a levonorgestrel-releasing intrauterine system and a depot GnRH

analogue for the treatment of chronic pelvic pain in women with endometriosis. Hum Reprod. 2005;20:1993.

Wong AY et al. Levonorgestrel-releasing intrauterine system (Mirena) and Depot medroxyprogesterone acetate

(Depoprovera) as long-term maintenance therapy for patients with moderate and severe endometriosis: a

randomised controlled trial. Aust N Z J Obstet Gynaecol. 2010;50:273.

The Practice Committee of the American Society for Reproductive Medicine. Treatment of pelvic pain

associated with endometriosis. Fertil Steril. 2006;86(Suppl 4):S18.

Crosignani P et al. Advances in the management of endometriosis: an update for clinicians. Hum Reprod

Update. 2006;12:179.

Pavone ME, Bulun SE. Aromatase inhibitors for the treatment of endometriosis. Fertil Steril. 2012; 98:1370–

1379.

Soysal S et al. The effects of post-surgical administration of goserelin plus anastrozole compared with goserelin

alone in patients with severe endometriosis: a prospective randomized trial. Hum Reprod. 2004;19:160.

Gibran L et al. Could statins constitute a novel treatment for endometriosis? Systematic review of the literature.

Eur J Obstet Gynecol Reprod Biol. 2014;179:153–158.

Carr B et al. Elagolix, an oral GnRH antagonist, versus subcutaneous depot medroxyprogesterone acetate for

the treatment of endometriosis: effects on bone density. Reprod Sci. 2014;21:1341–1351.

Sinaii N et al. Treatment utilization for endometriosis symptoms: a cross-sectional survey study of lifetime

experience. Fertil Steril. 2007;87:1277.

Crosignani PG et al. Subcutaneous depot medroxyprogesterone acetate versus leuprolide acetate in the

treatment of endometriosis associated pain. Hum Reprod. 2006;21:248.

Bedaiwy M, Casper RF. Treatment with leuprolide acetate and hormonal add-back for up to 10 years in stage

IV endometriosis patients with chronic pelvic pain. Fertil Steril. 2006;86:220.

Matsuo H. Prediction of the change in bone mineral density induced by gonadotropin-releasing hormone agonist

treatment for endometriosis. Fertil Steril 2004;81:149.

Melton LJ 3rd et al. Long-term fracture risk among women with proven endometriosis. Fertil Steril.

2006;86:1576.

The Practice Committee of the American Society for Reproductive Medicine. Endometriosis and infertility: a

committee opinion. Fertil Steril. 2012;98(3):591–598.

Ozkan S et al. Endometriosis and infertility: epidemiology and evidence-based treatments. Ann N Y Acad Sci.

2008;1127:92.

141.

142.

143.

144.

145.

146.

147.

148.

149.

150.

151.

152.

153.

154.

155.

156.

157.

158.

159.

160.

161.

162.

163.

164.

165.

166.

167.

168.

169.

170.

Tavmergen E et al. Long term use of gonadotropin releasing hormone analogues before IVF in women with

endometriosis. Curr Opin Obstet Gynecol. 2007;19:284.

Pearlstein T. Prevalence, impact, on morbidity and burden of disease. In: O’Brien P, Rapkin A, Schmidt P, eds.

The Premenstrual Syndromes: PMS and PMDD. London: Informa Healthcarel; 2007:37–47.

Campagne DM, Campagne G. The premenstrual syndrome revisited. Eur J Obstet Gynaecol Reprod Biol.

2007;130:4

O’Brien PMS et al. Towards a consensus on diagnostic criteria, measurement and trial design of the

premenstrual disroders: the ISPMD Montreal consensus. Arch Womens Ment Health. 2011;14:13–21.

American College of Obstetricians and Gynecologists. ACOG Practice Bulletin. Clinical management guidelines

for obstetrician-gynecologists. Premenstrualsyndrome. April 2000. Obstet Gynecol. 2000;95(4):1–9.

Braverman PK. Premenstrual syndrome and premenstrual dysphoric disorder. J Pediatr Adolesc Gynecol.

2007;20:3.

American Psychiatric Association. Diagnostic and Statistical Manual of Mental Disorders. 5th ed. (DSM-V).

Arlington, VA: APA; 2013.

Mishell DR Jr. Premenstrual disorders: epidemiology and disease burden. Am J Manag Care.

2005;11(Suppl):S473.

Dalton K et al. Incidence of premenstrualsyndrome in twins. BMJ. 1987;295:1027.

Van der Akker OB et al. Genetic and environmental variation in 2 British twin samples. Acta Genet Med

Gemellol. 1987;36:541.

Perkonigg A et al. Risk factors for premenstrual dysphoric disorder in a community sample of young women: the

role of traumatic events and posttraumatic stress disorder. J Clin Psychiatry. 2004;65:1314.

Mortola JF. Premenstrualsyndrome-pathophysiologic considerations. N EnglJ Med. 1998;338:256.

Halbreich U et al. Low plasma gamma-aminobutyric acid levels during the late luteal phase of women with

premenstrual dysphoric disorder. Am J Psychiatry. 1996;153:718.

Steiner M, Pearlstein T. Premenstrual dysphoric disorder and the serotonin system: pathophysiology and

treatment. J Clin Psychiatry. 2000;61(Suppl 12):17.

Nevatte T et al. ISPMD consensus on the management of premenstrual disorders. Arch Womens Ment Health.

2013;16:279.

Thys-Jacobs S, Alvir MJ. Calcium-regulating hormones across the menstrual cycle: evidence of a secondary

hyperparathyroidism in women with PMS. J Clin Endocrinol Metab. 1995;80:2227.

Thys-Jacobs S et al. Calcium supplementation in premenstrualsyndrome. J Gen Intern Med. 1989;4:183.

Penland JG, Johnson PE. Dietary calcium and manganese effects on menstrual cycle symptoms. Am J Obstet

Gynecol. 1993;168:1417.

Thys-Jacobs S et al. Calcium carbonate and the premenstrual syndrome: effects on premenstrual and menstrual

symptoms. Am J Obstet Gynecol. 1998;179:444.

Rosenstein DL et al. Magnesium measures across the menstrual cycle in premenstrual syndrome. Biol

Psychiatry. 1994;35:557.

Stevinson C, Ernst E. Complementary/alternative therapies for premenstrual syndrome: a systematic review of

randomized controlled trials. Am J Obstet Gynecol. 2001;185:227.

Ebadi M, Govitrapong P. Pyridoxal phosphate and neurotransmitters in the brain. In Tryiates G, ed. Vitamin B6:

Metabolism and the Role in Growth. Westport, CT: Food and Nutrition Press; 1980:223.

Wyatt KM et al. Efficacy of vitamin B-6 in the treatment of premenstrual syndrome: systematic review. BMJ.

1999;318:1375.

Dittmar G et al. Premenstrualsyndrome: treatment with a phytopharmaceutical. TW Gynakol. 1992;5:60.

Schellenberg R. Treatment for the premenstrual syndrome with agnus castus fruit extract: prospective,

randomised, placebo controlled study. BMJ. 2001;322:134.

Ma L et al. Treatment of moderate to severe premenstrual syndrome with Vitex agnus castus (BNO 1095) in

Chinese women. Gynecol Endocrinol. 2010;26(8):612–616.

Girman A et al. An integrative medicine approach to premenstrual syndrome. Am J Obstet Gynecol.

2003;188:S56.

Cho SH, Kim J. Efficacy of acupuncture in management of premenstrual syndrome: a systematic review.

Complement Ther Med. 2010;18:104.

Steiner M et al. Expert guidelines for the treatment of severe PMS, PMDD, and comorbidities: the role of

SSRIs. J Womens Health (Larchmt). 2006;15:57.

Majoribanks J et al. Selective serotonin reuptake inhibitors for premenstrualsyndrome. Cochrane Database Syst

171.

172.

173.

174.

175.

176.

177.

178.

179.

Rev. 2013;(6):CD001396. doi:10.1002/14651858.CD001396.pub3.